**LIVER DISEASE KNOWLEDGE AND ACCEPTABILITY OF NON-INVASIVE LIVER FIBROSIS ASSESSMENT AMONG PEOPLE WHO INJECT DRUGS IN THE DRUG AND ALCOHOL SETTING: THE LIVERLIFE STUDY**

Marshall AD1, Micallef M1, Erratt A1, Telenta J2, Treloar C3, H. Everingham4, Jones SC2, Bath N4, How-Chow D5, Byrne J6, Harvey P7, Dunlop A8,9, Jauncey M6, Read P1,10, Collie T11, Dore GJ1 andGrebely J1

1The Kirby Institute, UNSW Australia, NSW Australia; 2Centre for Health and Social Research, Australian Catholic University, VIC Australia; 3Centre for Social Research in Health, UNSW Australia, NSW Australia; 4NSW Users and AIDS Association, Inc., NSW Australia; 5St Vincent’s Hospital Sydney, NSW Australia; 6Australian Injecting and Illicit Drug Users League, ACT Australia; 7Hepatitis NSW, Australia; 8University of Newcastle, Newcastle, NSW Australia; 9Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, NSW Australia; 10Kirketon Road Centre, NSW Australia; 11Coffs Harbour Drug and Alcohol Service, NSW Australia

**Background:** Liver disease burden among people who inject drugs (PWID) is high, yet few strategies to enhance liver disease screening have been evaluated. The aim of this study was to assess factors associated with baseline knowledge of HCV and liver disease, acceptability of transient elastography (TE) assessment (FibroScan®), and willingness to receive HCV treatment among PWID participating in a liver health promotion campaign.

**Methods:** The LiveRLife campaign involved: 1) educational resource development; 2) resource testing; and 3) implementation. Between May-October 2014, participants were enrolled in an observational cohort study with recruitment from four clinics in Australia [one targeted primary healthcare facility, two opioid substitution treatment clinics, and one medically supervised injecting centre]. Participants received educational material, clinical assessment, TE assessment, dried blood spot testing, and completed a knowledge survey.

**Results:** Of 253 participants (mean age 43 years), 68% were male, 71% had injected in the past month, and 75% self-reported as HCV positive. Median knowledge score was 16/23. In adjusted analysis, high knowledge (≥16) was associated with <daily injection (AOR 5.01; 95% CI, 2.64-9.51) and no daily injection in the past month (AOR 3.54; 95% CI, 1.80-6.94). Of three screening options (TE, liver biopsy and blood sample), TE was the most preferred method pre- (66%) and post-TE (89%). Most participants (88%) were 'definitely' or 'somewhat willing' to receive HCV treatment and 56% intended to start treatment in the next year. Overall, 68% had no/mild fibrosis (F0/F1, ≥2.5 - ≤7.4 kPa), 13% moderate fibrosis (F2, ≥7.5 - ≤9.4 kPa), 10% severe fibrosis (F3, ≥9.5 - ≤12.4 kPa), and 9% had cirrhosis (F4, ≥12.5 kPa). Sixty percent (n=152) returned for a follow-up nurse/specialist assessment.

**Conclusion:** Acceptability of TE was high and the majority of people returned for a follow-up assessment by a nurse/specialist, supporting the inclusion of TE in HCV-related care.

**Disclosure of Interest Statement:** The study was funded from MSD, Australia. The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. GD is supported by a National Health and Medical Research Council Practitioner Research Fellowships. JG is supported by a National Health and Medical Research Council Career Development Fellowship. SJ is supported by an Australian Research Council Future Fellowship.